Gene Signal, a company focused on developing innovative drugs tomanage angiogenesis based conditions, has announced that positivedata from a study of aganirsen (GS-101, eye drops) in a nonhumanprimate model of choroidal neovascularization has been presented atthe 2012 ARVO Annual Meeting in Fort Lauderdale, Florida. Topicaladministration of aganirsen was found to inhibit neovascular growthand leakage in this model and strongly suggests a role for the drugcandidate in human retinal neovascular diseases such as wetage-related macular degeneration (AMD) and ischemic retinopathy. Gene Signal's aganirsen is anantisense oligonucleotide that is expected to complete a phase IIItrial for the treatment of progressive neovascularisation in thecornea in 2012. Clinical studies in retinal diseases are scheduleto begin during the second quarter 2012. "This study demonstrates the ability of aganirsen to addressneovascularization formation in the retina by inhibiting theexpression of the angiogenic protein IRS-1. Importantly, this isachieved without affecting normal vascularisation," noted Dr.Matthew Lawrence of RxGen, Inc, who presented the data. "With thedemand for new, effective antiangiogenic agents that are easier touse in the treatment of several eye diseases growing, we believethese data strongly support a role for aganirsen." Aganirsen blocks pathological neovascularization by inhibitingIRS-1. Clinical studies to date have shown that aganirsen is ableto safely and effectively inhibit the development of progressivecorneal neovascularization secondary to infectious keratitis orchemical burns both of which could lead to corneal graftreplacement. "A topical agent for neovascular disease would revolutionizetreatment. There is a huge unmet need for many opthalmologicaldiseases including AMD, ischemic retinopathy and certain forms of glaucoma ," noted Eric Viaud, CEO of Gene Signal. "To confirm the manyadvantages that topical aganirsen could offer over currentlyavailable drugs, we intend to begin Phase II clinical evaluation inthe next few months. We also acknowledge that a group of worldleading experts have agreed to discuss the future development ofaganirsen during the current ARVO conference. Their insight isinvaluable and gratefully accepted by our team." Study Details: Aganirsen (topical emulsion) was applied daily innon-human primates following laser induced choroidalneovascularisation (CNV), a model of wet age-related maculardegeneration (AMD). Retinal aganirsen concentrations were assessedin monkeys following topical delivery (21.5, 43 or 86 g). Aganirsenwas found to inhibit dose-dependently neovascular lesiondevelopment, with the incidence of high-grade CNV lesions (gradeIV, as measured by fluorescein signal intensity) decreasing from20.5% in vehicle-treated animals to 1.7% (p 0.05) in animalstreated with the highest dose of Aganirsen (86 g/day). The sizeof neovascularization complexes was also significantly lower ineyes receiving high dose and low dose aganirsen (p 0.0001)compared with vehicle-treated eyes. Additional References Citations. I am an expert from songiclaser.com, while we provides the quality product, such as China Yag Laser Hair Removal Machine , Erbium Yag Laser Manufacturer, Yag Laser Hair Removal Machine,and more.
Related Articles -
China Yag Laser Hair Removal Machine, Erbium Yag Laser Manufacturer,
|